Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927731 | 1.00 | PDE4B (0.61) | PDE4BPDE4DADORA1 | |
| SCHEMBL4937556 | 0.95 | PDE4B (0.61) | PDE4BPDE4DADORA1 | |
| SCHEMBL4935454 | 0.94 | PDE4B (0.59) | PDE4BPDE4DADORA1 | |
| SCHEMBL4931599 | 0.92 | PDE4B (0.61) | PDE4BPDE4DADORA1 | |
| SCHEMBL4934554 | 0.92 | PDE4B (0.58) | PDE4BPDE4DADORA1 | |
| SCHEMBL4936769 | 0.92 | PDE4B (0.60) | PDE4BPDE4DADORA1 | |
| SCHEMBL4936192 | 0.92 | PDE4B (0.60) | PDE4BPDE4DADORA1 | |
| SCHEMBL4935368 | 0.91 | PDE4B (0.57) | PDE4BPDE4DADORA1 | |
| SCHEMBL2771244 | 0.91 | PDE4B (0.72) | PDE4BADORA1 | |
| SCHEMBL4935453 | 0.91 | PDE4B (0.60) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | claimed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 7/4885ADORA1 285/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885PDE4D 9/4885ADORA1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.